Evidence map›Paper›PMID 41877749›Full record

ArticleEcancermedicalscience2026

The 19th St. Gallen international breast cancer conference 'primary therapy of patients with early breast cancer. Evidence, controversies, consensus': key moments and breakthroughs.

Consuelo Morigi

Abstract read
In one paragraph

Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Consuelo MorigiDivision of Breast Surgery, IRCCS European Institute of Oncology, 20141 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 19th St. Gallen International Breast Cancer Conference took place at the Austria Centre in Vienna from March 12th to 15th, 2025. The event achieved remarkable success, drawing over 3,100 participants from all over the world. This accomplishment is attributable to the high calibre of scientific lectures presented by leading global experts in breast cancer (BC) treatment, the opportunity for the audience to interact with panellists through questions, the interesting and varied scope of submitted posters, the debates that punctuated the many sessions, and notably, the renowned St. Gallen Consensus Session. This year's Opening Ceremony held particular significance. In commemoration of the Swiss physician and oncologist Hansjoerg Senn, who passed away in 2023, the Hansjoerg Senn Memorial Lecture was instituted to honour his profound contributions to the treatment and care of patients, particularly those affected by BC. The Memorial Lecture serves as a platform to recognise and celebrate individuals who have significantly advanced BC research. The recipient is presented with the St. Gallen Breast Cancer Award and invited to deliver an address at the opening ceremony of the St. Gallen International Breast Cancer Conference. This year, this prestigious award was presented to Prof. Armando E. Giuliano, who delivered an insightful lecture entitled 'My Personal Experience: Changing Surgery for BC.' In it, drawing from his impressive surgical career during which he changed the standard of care-exemplified by the sentinel lymph node procedure and the Z0011 study-he spoke about how change, though difficult, is both necessary and inevitable, emphasising that no one is too young or too old to change.

Indexed as

19th St Gallen consensus conference 2025adjuvant therapiesartificial intelligenceconsensusearly breast cancerneoadjuvant chemotherapySGBCC 2025surgerytrials

Identifiers

PMID41877749
PMCPMC13006546

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.